Even in an era of HAART Drugs, HIV patients are vulnerable to opportunistic infections

SAN FRANCISCO -- Despite the effectiveness of antiretroviral drugs, HIV patients are still very vulnerable to opportunistic infections, according to new research by AIDS specialists at the University of California, San Francisco.

This vulnerability has important implications for developing optimum treatment strategies, the UCSF researchers emphasize.

In presentations at the Interscience Conference on Anti-Microbial Agents and Chemotherapy here today (September 27), the researchers reported study findings on two different infections common in HIV patients and how they relate to highly active antiretroviral therapy, known as HAART.

There is only limited information on the impact of HAART on AIDS-related opportunistic infections because it is still a recent treatment approach. Initiated three years ago, HAART uses a combination of powerful drugs, including protease inhibitors and reverse transcriptase inhibitors, to subdue HIV infection and give the body the chance to increase its supply of infection-fighting CD4+ T-cells that are destroyed by HIV.

One of the new research reports focused on the incidence of cytomegalovirus (CMV) retinitis, a serious eye disease that can lead to blindness. The second looked at development of drug resistance in the respiratory tract of HIV patients who underwent prophylaxis therapy to prevent a bacterial infection caused by Mycobacterium avium complex (MAC), which causes serious illness that ultimately leads to wasting and death if untreated.

Findings from the CMV research were both good and bad, said Mark Jacobson, MD, lead investigator and a UCSF associate professor of medicine who treats patients at San Francisco General Hospital Medical Center.

An objective of the study was to look at the natural history and outcome of new AIDS-related CMV retinitis cases, both before and during HAART. The study included HIV patients with newly diagnosed retinitis between 1994-1999.

"On the positive side, the inciden

Contact: Corinna Kaarlela
University of California - San Francisco

Page: 1 2 3

Related medicine news :

1. Most episodes of HIV blips not clinically significant in patients receiving HAART
2. Multiple characteristics of HAART affect adherence
3. Researchers examine the use of antiretroviral therapy among injection drug users with HIV infection: Study suggests addiction treatment and health care contribute to HAART enrollment
4. ICAAC highlight: MAC prophylaxis can be safely discontinued in HIV-infected patients who respond to HAART
5. Old Drugs, New Tricks
6. Hormonal treatment improves survival in high-risk prostate cancer patients
7. Study finds that coordinating care of chronically ill patients does not increase liability
8. Mouse model reveals potential way to reduce cardiac deaths in kidney patients
9. Optical technique identifies vulnerable plaques in cardiac patients
10. NHS target driven culture is failing patients
11. Cardiac deaths peak in sleep hours for patients with sleep apnea

Post Your Comments:

(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically ... announced three leadership team developments today:   ... ... Tom ... Veteran medical device executive Josh Stopek , PhD, who ...
Breaking Medicine Technology:
Cached News: